CSL (ASX:CSL) shares rebound A$16 billion off lows, lag plasma sector for week
CSL Limited has regained roughly A$16 billion in market value from its 52-week low, but last week's slight rise lagged behind two competitors involved in plasma.
CSL Limited (ASX:CSL) awaits US$650 million hurdle ahead of August results, pressuring rebound
CSL Limited gained 1.12% to close at A$123.32 on Friday. The S&P/ASX 200 index slipped 0.50%. Sydney’s cash market remained closed on Saturday morning.
CSL Share Price Has Won Back A$15 Billion — Now Investors Want Revenue Proof
CSL Limited entered Tuesday’s ASX pre-open after falling 1.26% to A$121.34 on Monday, while the S&P/ASX 200 edged 0.03% higher. Turnover reached 1.50 million shares, 34% above the average of the previous five sessions. The exchange remained in pre-open at publication, with continuous trading due to begin around 10 a.m. Sydney time.
Australian Securities Exchange Weekly Wrap: ASX 200 Sheds A$130 Billion as Middle East War and Rate Risks Rattle Stocks
Australian stocks took a hard hit last week, with the S&P/ASX 200 tumbling 3.8% amid escalating concerns over the Middle East conflict. Investors saw around A$130 billion in value erased from the market. On Friday, the index sank another 1%, which wiped out close to half the gains made in February.
CSL share price ticks up on buyback update as investors line up key March dates
CSL Limited settled 0.5% higher at A$146.76 Friday, having swung from A$145.07 to A$147.53 through the session as roughly 1.68 million shares traded. The stock finished just about A$2 clear of its 52-week low at A$144.61, according to data.
CSL share price slips again as buyback rolls on, March dividend date looms
CSL Ltd closed down 1.5% on Tuesday at A$145.13, slipping from an open of A$148.10 before ending the day on the session’s low. The stock has now dropped 5.3% across the last two sessions.
CSL share price slips as buyback tally grows; Lilly deal sets up next week
CSL Ltd slipped 0.6% Friday, ending the session at A$153.27. That pullback shaved off some of the gains from a two-day run-up earlier in the week.
CSL stock price ends higher after Eli Lilly clazakizumab deal, with buyback in the background
CSL Ltd jumped up to 2.1% on Wednesday after the Australian biotech signed a licensing agreement with Eli Lilly for clazakizumab, an investigational antibody currently in trials for end-stage kidney disease.
CSL share price slips after fresh buyback filing — what investors watch next
CSL Limited slipped 0.4% to finish at A$151.56 on Tuesday, lagging behind the S&P/ASX 200’s 0.2% gain. The stock has lost roughly 14% since early February, hit by a steep drop during profit season.
ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%
Australian stocks closed almost flat Tuesday, the S&P/ASX 200 shedding just 2.7 points, or 0.03%, to settle at 8,867.40. Insurance brokers took a hit as renewed AI competition fears surfaced. Miners, gold names, and tech all moved higher. “A peer releasing an app has wiped billions off the market capitalisations of the insurance broking sector,” said Luke Winchester, portfolio manager at Merewether Capital.
CSL CEO exit jolts ASX even as Nvidia lifts tech mood
CSL shares slid 4.98% Tuesday after the Australian biotech announced CEO Paul McKenzie’s retirement and tapped director Gordon Naylor as interim chief, effective Feb. 11. The S&P/ASX 200, which spent much of the day in positive territory, ended almost flat—off 0.03% at 8,867.4.
CSL CEO Paul McKenzie retires ahead of results, sending shares lower as Gordon Naylor steps in
CSL announced Tuesday that chief executive and managing director Paul McKenzie is stepping down. Gordon Naylor, a veteran executive at the company, will assume the interim CEO role starting Feb. 11.
CSL share price rises as CEO McKenzie steps down, spotlight turns to half-year results
CSL Ltd announced chief executive Paul McKenzie’s retirement, tapping former executive Gordon Naylor as interim replacement. Shares in CSL ended Tuesday 1.7% higher at A$183.44.
CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results
CSL Limited slipped 0.4% to finish at A$180.50 on Friday, with the ASX healthcare giant showing limited action as investors wait for its half-year results next week. Shares moved between A$179.29 and A$183.31 during the session.
Australia stock market today: ASX 200 slumps 2% as miners and tech drag, earnings week looms
Australian shares plunged on Friday, with the S&P/ASX 200 dropping 2.03% to 8,708.80. Web Travel Group took a heavy hit, tumbling 29.52%, and Paladin Energy slid 10.92%. Brambles was one of the few bright spots, edging up 3.48% amid a sparse field of winners.
CSL share price dips in ASX rout — here’s what investors are watching before earnings
CSL Limited slipped 0.41% to finish at A$180.50 on Friday, with intraday trading ranging from A$179.29 to A$183.30. Roughly 1.23 million shares were exchanged, compared to a prior close of A$181.24, according to data from Investing.com.
CSL Limited share price rises 2% on ASX — what to know ahead of Feb 11 results
CSL Limited’s shares climbed 2.0% to close at A$181.70 on Wednesday, adding A$3.59. The stock fluctuated between A$182.04 at its peak and A$176.59 at its low during the session. Over the last 52 weeks, the price has ranged from A$168.00 to A$275.79.
CSL shares bounce after Monday dip as investors eye Feb 11 results — what matters now
CSL Limited shares climbed 0.58% to close at A$178.11 on Tuesday, bouncing back after a 2.39% fall in the previous session. The broader S&P/ASX 200 index gained 0.89%. The stock fluctuated between A$177.93 and A$179.91, with the last trade occurring shortly after the market closed.
CSL share price drops 2.4% as investors turn to Feb 11 half-year results webcast
CSL Limited shares dropped 2.39% to close at A$177.08 on Monday, hitting a low of A$176.18 after opening at A$182.00. The stock remains roughly 36% off its 52-week peak, with around 1.01 million shares traded.
CSL share price: Two dates now loom after Friday’s lift
CSL Limited shares closed Friday at A$181.42, rising A$2.02 or 1.13%. The stock fluctuated between A$181.00 and A$184.41 during the session, remaining far below its 52-week peak of A$277.92.